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Abstract Intramuscular injection of diclofenac is still
frequently practiced, although there is ample evidence that
the risk of local tissue intolerability is highly underesti-
mated. The aim of this study was to evaluate local toxicity
in a patient using magnetic resonance imaging. A patient
who gave written informed consent received a medically
indicated intramuscular administration of diclofenac
75 mg/2 mL. Simultaneously with magnetic resonance
imaging of the depot, a clinical–chemical evaluation and
quantification of diclofenac in plasma was performed. A
manifold enhancement of the T2-weighted magnetic reso-
nance signal was observed in a muscle area of approxi-
mately 60 mL volume, with maximum signal intensity
30 min after injection, the time of maximum diclofenac
plasma exposure. Plasma creatine kinase activity was ele-
vated approximately sixfold within 8 h and normalized
within 1 week, whereas the magnetic resonance enhance-
ment disappeared within 5 weeks. Interestingly, the patient
did not complain about any clinical symptoms at the
injection site. Asymptomatic tissue injury after intramus-
cular injection of diclofenac, caused by intramuscular
dosing, can be reliably evaluated by magnetic resonance
imaging and should be applied early during the develop-
ment of parenteral dosage forms.
Clinical Trials Registration Number: BB130/16 (Ethics
Committee of the University Medicine Greifswald).
Key Points
Local tissue injury following intramuscularly
administered diclofenac can be proven noninvasively
by magnetic resonance imaging.
Introduction
The relief of acute pain syndromes by administration of
intramuscular injections of diclofenac is still frequently
practiced and seems to be a safe and well-tolerated treat-
ment option. The incidence of local adverse events seems
to be rather low—0.05% for abscesses and 0.02% for
necrosis [1]. Common reasons for local complications are
bacterial contamination [2], wrong injection technique, and
wrong injection site [3]. Therefore, obligatory guidelines
for safe intramuscular injection, including site, dose, and
injection technique, are provided by the manufacturers of
parenteral diclofenac dosage forms; however, the safety
issue seems to be highly underestimated. In a survey con-
ducted between 1978 and 2003, only 171 cases with local
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injuries, including necrosis, abscess, necrotizing fasciitis
and myositis, were related to the consumption of 100
million ampules of Voltarol, and only nine patients
complained of pain at the injection site [4].
Since local tissue injury after diclofenac is rarely asso-
ciated with relevant subjective symptoms, it can be
assumed that many cases are not recognized in clinical
practice. The issue may be more severe than assumed to
date. In a recent experimental study in rats to investigate
the disposition of intramuscularly injected depots, we
incidentally observed that all animals that received an
aqueous solution or oily suspension of diclofenac respon-
ded with local inflammatory intolerance [5]. This included
long-lasting fluid accumulation at the site of intramuscular
injection and infiltration of the muscle tissue with neu-
trophil granulocytes, as well as the development of necrotic
changes as confirmed by magnetic resonance (MR) imag-
ing and histopathological evaluation. The severity of
inflammation was dependent on dose and the pharmaceu-
tical formulation of the drug. To support our hypothesis
that intramuscular injection of diclofenac leads to muscle
damage in humans, we provide the clinical case report of a
patient who gave written consent to take extra blood
specimens for laboratory evaluations and determination of
diclofenac pharmacokinetics, as well as for MR imaging
after a medicinally indicated intramuscular diclofenac
injection.
Methods
A physician (aged 65 years, body weight 90 kg, body
height 182 cm) who is familiar with the safety issue
described above, prescribed himself an intragluteal injec-
tion of diclofenac (Diclofenac-Ratiopharm 75 mg/2 mL;
Ratiopharm, Ulm, Germany) as a result of a painful
enthesopathy of the right musculus gluteus minimus, and
initiated additional clinical–chemical evaluations and MR
imaging of the left gluteal region to evaluate a potential
muscle injury at the injection site. The diagnosis was
confirmed by MR imaging approximately 1 year prior to
commencement of the study. The patient commonly
swallowed ibuprofen lysine (684 mg) or diclofenac
(50 mg) on demand, i.e. after the occurrence of pain fol-
lowing stronger physical exercise. This treatment has been
well tolerated. The additional diagnostic procedures have
been approved by the local ethics committee under registry
number BB130/16. The osmolality of the aqueous
diclofenac solution was 2850 ± 121 mOsmol/kg (Vapour
Pressure Osmometer; Knauer, Berlin, Germany) and the
pH was 8.19 ± 0.03 (Five Easy; Mettler Toledo, Grei-
fensee, Switzerland). MR imaging in the supine position
was performed using a 3-Tesla scanner (Verio; Siemens
Healthcare, Erlangen, Germany) before and 2, 12, 22, 32,
47, 62, 92, 122, 182, 242 min after, as well as 7.5 h and 1,
2, 7 and 14 days after intramuscular administration. A T2-
weighted turbo spin echo sequence including fat saturation
was applied with the following parameters: 6960 ms rep-
etition time, 91 ms echo time, 60 slices of 2-mm thickness
and 2-mm spacing in between, 150  flip angle,
450 9 370 mm field of view, and 256 9 170 mm matrix.
Volume and signal intensity of the depot was assessed
using the OsiriX Imaging Software 3.9 32-Bit (Pixmeo
Sarl, Bernex, Switzerland). Blood was sampled via an
indwelling cannula placed in a forearm vein before and 10,
20, 30 and 45 min after, as well as 1, 1.5, 2, 2.5, 3, 3.5, 4, 5,
6, 8 and 24 and 48 h after administration to measure
plasma concentrations of diclofenac and the biomarkers
creatine kinase (CK), C-reactive protein (CRP), Procalci-
tonin (PCT) and Interleukin-6 (IL-6). Quantitative analysis
of diclofenac concentration in plasma was performed using
a validated liquid chromatography-tandem mass spec-
trometry (LC–MS/MS) method as previously described [5].
The biomarkers were quantified using commercially
available kits for PCT (ADVIA Centaur; Siemens Health-
care, Eschborn, Germany), IL-6 (Brahms, Hennigsdorf,
Germany; and Cobas e411, Roche, Mannheim, Germany),
CRP and CK (Dimension Vista; Siemens Healthcare,
Eschborn, Germany). All measurements were carried out
according to the instructions of the manufacturer, and
complied with the national regulations on laboratory
quality assurance [6].
Results
The patient did not complain of pain and other symptoms
at the site of diclofenac administration, neither immedi-
ately nor some time after the injection, despite the
expectant attitude of the informed subject. The contralat-
eral tendinous gluteal pain was relieved for approximately
4 h but occurred again thereafter, however with tolerable
intensity.
Shortly after intragluteal administration of diclofenac
75 mg in 2 mL aqueous solution, the recovered volume at
the injection site was approximately 6 mL, as measured
using T2-weighted, MR-based volumetry. The depot vol-
ume increased to 37 mL within 45 min, then decreased to
17 mL after approximately 4 h, before it increased again to
reach a maximum of 60 mL 24 h after injection. The
watery inhomogeneity was seen in the MR images over
several weeks. The T2-weighted signal enhancement,
quantified as contrast-to-noise ratio (CNR), reached its
maximum just immediately after injection, and then
declined rapidly within 2 h to a long-lasting plateau level
that disappeared after several weeks (Figs. 1, 2).
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After intramuscular injection, diclofenac reached a
maximum plasma concentration of approximately 1.4 lg/
mL after 30 min and was eliminated in a biphasic manner,
with half-lives of 0.63 h (a-slope) and 1.36 h (b-slope).
Plasma creatine kinase activity was elevated more than
sixfold within 8 h after diclofenac injection, and returned
to baseline levels after 1 week (Fig. 2). Plasma concen-
trations of CRP, PCT and IL-6 were not changed from
baseline after diclofenac administration.
Fig. 1 T2-weighted transverse magnetic resonance images of the left gluteal region before and after a 2 mL injection of diclofenac watery
solution. Arrows indicate the site of injection and volume of the enhanced muscle tissue
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Discussion
The single MR-guided intramuscular injection of diclofe-
nac 75 mg in 2 mL solution unexpectedly damaged
approximately 60 mL of gluteal muscle tissue of the
patient, as confirmed by long-lasting, manifold enhance-
ment of the T2-weighted MR signal in that area and ele-
vation of the plasma CK activity for longer than 48 h.
Initially, the tissue damage was most likely triggered by
local ion disequilibrium caused by infiltration of the highly
hypertonic solution (2850 mOsmol/kg). This resulted in
rapid enhancement of the T2-weighted MR signal, with
maximum signal intensity approximately 30 min after
injection, which was also the time of maximum diclofenac
plasma exposure. This means that diclofenac must have
been almost fully absorbed from the injection depot at that
time. Consequently, the highest volume of the injured
muscle area being detected 24 h after the injection cannot
be explained by the osmotic pressure of the injected solu-
tion alone.
Diclofenac is known to induce organ injury indirectly by
inhibition of the cyclooxygenase (e.g. gastrointestinal
erosions and bleedings, renal tubular damage) or by
metabolic activation of reactive metabolites that exert cell
stress, impair mitochondrial functions, or trigger specific
immune reactions in genetically predisposed subjects (e.g.
drug-induced liver injury) [7]. However, tissue injury after
intramuscular injection into the recommended gluteal
region is most likely caused by direct cytotoxicity, as
already observed in gastric mucosal cells [8], osteoblasts
[9], and tumor cells [10]. Cell death is likely induced by
activation of the caspase signaling cascade, leading to
proteolytic fragmentation of DNA and degradation of the
cells [11], even though the activation mechanisms of the
proapoptotic signal pathways by diclofenac have not been
fully understood to date. However, local toxicity of
diclofenac can be influenced by the pH-dependent solu-
bility of the drug [12]. Traces of diclofenac might precip-
itate at the injection site even after a minor drop in the pH
value, as caused by local tissue congestion, ion disequi-
librium, or inflammatory changes, leading to longer lasting
exposure of the affected area and perpetuation of the local
toxicity. The plasma CK activity, a biomarker for the
muscle tissue injury, was already elevated 1 h after injec-
tion of the drug and reached its maximum, at the earliest,
after 8 h (Fig. 2). The biphasic elimination profile, with
half-lives of 0.63 and 1.4 h, supports the hypothesis that
parts of the dose are absorbed from a depot with a slower
input rate. Furthermore, the patient did not complain of any
pain at the injection site, as expected by the extent of the
putative muscle injury visualized by MR imaging. The
contradiction between the impressive morphological and
laboratory signs and lack of clinical symptoms might also
result from long-lasting tissue deposition of diclofenac,
which is known to exert local anesthetic effects [13, 14]. In
that context, it should be reminded that every single rat in
our previous experimental study showed a massive T2
enhancement at the injection site [5].
Conclusion
Asymptomatic tissue injury after intramuscular adminis-
tration of diclofenac seems to be a frequent or regular local
finding, even though the injection technique is fully in
adherence with the obligatory guidelines for intramuscular
Fig. 2 CNR of the T2-
enhanced muscle area (filled
square), plasma concentrations
of diclofenac (ng/mL, filled
circle), and activity of creatine
kinase (lkatal/L, filled triangle)
after intramuscular injection of
diclofenac 75 mg in a 2-mL
solution. CNR contrast-to-noise
ratio
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administration in humans. Therefore, intramuscular injec-
tion of diclofenac should be carefully practiced, focusing
on the individual benefit–risk balance. To our experience,
local toxicity caused by intramuscular dosing of drugs can
be reliably evaluated by non-invasive MR imaging, and
should be applied in the very early stages of the evaluation
of parenteral dosage forms.
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